Singh Raj, Stoltzfus Kelsey C, Chen Hanbo, Louie Alexander V, Lehrer Eric J, Horn Samantha R, Palmer Joshua D, Trifiletti Daniel M, Brown Paul D, Zaorsky Nicholas G
Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, Virginia, USA.
Department of Radiation Oncology, Penn State Cancer Institute, Hershey, Pennsylvania, USA.
Neurooncol Adv. 2020 Jan-Dec;2(1):vdaa041. doi: 10.1093/noajnl/vdaa041. Epub 2020 Apr 24.
The objectives of this study were to characterize (1) epidemiology of brain metastases at the time of primary cancer diagnosis, (2) incidence and trends of synchronous brain metastases from 2010 to 2015, and (3) overall survival (OS) of patients with synchronous brain metastases.
A total of 42 047 patients with synchronous brain metastases from 2010 to 2015 were identified from the Surveillance, Epidemiology, and End Results database. Descriptive analysis was utilized to analyze demographics and incidence. The Kaplan-Meier method and a Cox proportional hazards model were utilized to evaluate potential prognostic factors for OS.
The majority of patients were diagnosed from age older than 50 (91.9%). Common primary sites included lung (80%), melanoma (3.8%), breast (3.7%), and kidney/renal pelvis (3.0%). Among pediatric patients, common primaries included kidney/renal pelvis and melanomas. The incidence was roughly 7.3 persons/100 000. Synchronous brain metastases were associated with significantly poorer OS compared to extracranial metastases alone (hazard ratio [HR] =1.56; 95% CI: 1.54-1.58; < .001). Among patients with brain metastases, male gender (HR = 1.60 vs 1.52), age older than 65 years (HR = 1.60 vs 1.46), synchronous liver, bone, or lung metastases (HR = 1.61 vs 1.49), and earlier year of diagnosis (HR = 0.98 for each year following 2010) were associated with significantly poorer OS.
The vast majority of brain metastases are from lung primaries. Synchronous brain metastases are associated with poorer OS compared to extracranial metastases alone.
本研究的目的是描述(1)原发性癌症诊断时脑转移瘤的流行病学特征,(2)2010年至2015年同步性脑转移瘤的发病率及趋势,以及(3)同步性脑转移瘤患者的总生存期(OS)。
从监测、流行病学和最终结果数据库中识别出2010年至2015年期间共42047例同步性脑转移瘤患者。采用描述性分析来分析人口统计学和发病率。采用Kaplan-Meier法和Cox比例风险模型来评估OS的潜在预后因素。
大多数患者诊断时年龄超过50岁(91.9%)。常见的原发部位包括肺(80%)、黑色素瘤(3.8%)、乳腺(3.7%)和肾/肾盂(3.0%)。在儿科患者中,常见的原发部位包括肾/肾盂和黑色素瘤。发病率约为7.3人/10万。与仅发生颅外转移相比,同步性脑转移瘤患者的OS明显更差(风险比[HR]=1.56;95%置信区间:1.54-1.58;P<0.001)。在脑转移瘤患者中,男性(HR=1.60 vs 1.52)、年龄大于65岁(HR=1.60 vs 1.46)、同步性肝、骨或肺转移(HR=1.61 vs 1.49)以及诊断年份较早(2010年后每年HR=0.98)与OS明显更差相关。
绝大多数脑转移瘤来自肺部原发肿瘤。与仅发生颅外转移相比,同步性脑转移瘤患者的OS更差。